Genprex

Rodney Varner, CEO, Chairman & President of Genprex, Inc. (NASDAQ: GNPX), was recently a guest on Benzinga’s All-Access. Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are...

A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that have limited treatment options. The company is working with world-class institutions in developing...

On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. To make matters worse, epidemiologic evidence suggests that people with diabetes — especially Type 2 diabetes — are at significantly higher...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. According to data from the World Health Organization, cancer is currently the second leading cause of death worldwide, and unfortunately,...

Benzinga will empower industry-wide innovation by featuring those businesses and individuals creating positive and diverse change at the 2020 Benzinga Global Small Cap Conference on Dec. 8-9, two days of deal-making, networking, and learning In bridging the gap between publicly traded companies,...

The number of biotech stocks posting gains outstripped those recording losses for the week. Notable among the gainers for the week were Odonate Therapeutics Inc (NASDAQ: ODT) — which reported its financial results Feb. 14 and has been rallying ever since — and ARMO Biosciences Inc...